Table. Study Characteristics of All Trials Included in the Meta-analysis.

Source	No. of participants	Mean age, y	Female, No. %	Study duration	Substance	Type of pain	Route of administration	Crossover design	Financial interest
Berman et al,13 2004	48	39	0	1.8 wk	Nabiximols	Neuropathic	Spray	Yes	Yes
Buggy et al,14 2003	40	48	40 (100)	6 h	THC	Other	Pill	No	No
Chaves et al,15 2020	17	52	9 (100)	8 wk	THC	Other	Oil	No	Yes
Corey-Bloom et al,16 2012	30	51	19 (63)	45 min	THC	MS	Smoked	Yes	No
De Vries et al,17 2017	50	52	11 (22)	12 wk	THC	Other	Pill	No	No
Issa et al,18 2014	29	51	16 (53)	8 h	Dronabinol	Other	Pill	Yes	No
Langford et al,24 2013	339	49	117 (68)	14 wk	THC or CBD	Multiple	Spray	No	Yes
Malik et al,25 2017	13	43	11 (85)	4 wk	Dronabinol	Other	Pill	No	No
Nurmikko et al,26 2007	125	53	74 (59)	5 wk	Nabiximols	Neuropathic	Spray	No	Yes
Rog et al,23 2005	63	49	52 (79)	4 wk	THC or CBD	MS	Spray	No	Yes
Schimrigk et al,19 2017	240	48	175 (73)	16 wk	Dronabinol	Neuropathic	Spray	No	Yes
Skrabek et al, 200820	40	50	37 (93)	4 wk	Nabilone	Other	Pill	No	No
Toth et al,21 2012	26	62	13 (50)	9 wk	Nabilone	Neuropathic	Pill	No	Yes
Turcott et al,22 2018	33	61	26 (79)	8 wk	Nabilone	Other	Pill	No	No
Wade et al,28 2003	24	48	12 (50)	6 wk	THC	Neuropathic	Spray	Yes	Yes
Wallace et al,27 2015	16	57	7 (44)	4 h	THC	Neuropathic	Vaporized	Yes	No
Ware et al,29 2010	23	45	12 (52)	2 wk	THC	Neuropathic	Pill	Yes	No
Weizman et al,30 2018	15	33	0	4 h	THC	Neuropathic	Spray	Yes	No
Zadikoff et al,31 2011	9	60	9 (100)	8 wk	Dronabinol	Neuropathic	Pill	Yes	No
Zajicek et al,32 2012	279	52	175 (65)	12 wk	THC or CBD	MS	Pill	No	No

Abbreviations: CBD, cannabidiol; MS, multiple sclerosis; THC, tetrahydrocannabinol.